Drug Type Small molecule drug |
Synonyms Eupatilin/jaceosidin, Jaceosidin/eupatilin, Stillen + [2] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (29 Apr 2005), |
Regulation- |
Molecular FormulaC18H16O7 |
InChIKeyDRRWBCNQOKKKOL-UHFFFAOYSA-N |
CAS Registry22368-21-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Gastritis | South Korea | 29 Apr 2005 | |
| Stomach Ulcer | South Korea | 29 Apr 2005 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anaphylaxis | Discovery | South Korea | 20 Mar 2005 | |
| Anaphylaxis | Discovery | South Korea | 20 Mar 2005 |
Phase 3 | 434 | avqbumreaz(xgmuapsqxl) = AEs were reported in 18 (8.4%) patients in the DA-5204 group and 19 (8.8%) in the DA-9601 group lvdvmooixu (djyygbysno ) | Positive | 01 Nov 2017 | |||
Phase 3 | 421 | DA-5204 (90 mg, b.i.d.) | jfpbpergvz(pxltescowo) = tiybxktivc izxziiprmb (asrrdxwsbo ) View more | Positive | 01 Oct 2016 | ||
DA-9601 (60 mg, t.i.d.) | jfpbpergvz(pxltescowo) = slorifdwyc izxziiprmb (asrrdxwsbo ) View more |





